| H01466 | |
| H number | H01466 |
| Name | Ulcerative colitis |
| Description | Ulcerative colitis (UC) is one subtype of inflammatory bowel disease (IBD) whose pathogenesis is multifactorial and includes influences from genes, the environment, and the gut microbiome. In UC the inflammatory is limited to the mucosa of the colon and rectum. Clinically, the most common manifestation of UC may include bloody diarrhea, abdominal pain. In most severe cases, patients may experience fever, weight loss, anemia, and the intestine can get distended, presenting deep ulceration and possibly intestinal perforation.The long-time duration of the disease increases a colorectal cancer risk. UC is associated with a Th2 immune response. Recent genetic analyses have linked genes including interleukin 23 receptor, interleukin 10 and macrophage stimulating 1. |
| Category | Immune system disease |
| Network | - |
| Gene | IL23R [HSA:149233] [KO:K05065] IL10 [HSA:3586] [KO:K05443] IL37 [HSA:27178] [KO:K05485] MST1 [HSA:4485] [KO:K23441] |
| Pathogen | Fusobacterium varium [GN:fva] |
| Env factor | - |
| Carcinogen | - |
| Drug | Triamcinolone acetonide [DR:D00983] Dexamethasone [DR:D00292] Dexamethasone sodium phosphate [DR:D00975] Hydrocortisone [DR:D00088] Hydrocortisone acetate [DR:D00165] Hydrocortisone sodium succinate [DR:D00978] Prednisolone [DR:D00472] Prednisolone sodium phosphate [DR:D00981] Prednisone [DR:D00473] Budesonide [DR:D00246] Sulfasalazine [DR:D00448] Mesalamine [DR:D00377] Olsalazine sodium [DR:D00727] Balsalazide disodium [DR:D02715] Methylprednisolone [DR:D00407] Methylprednisolone sodium succinate [DR:D00751] Methylprednisolone acetate [DR:D00979] Cortisone acetate [DR:D00973] Tofacitinib citrate [DR:D09783] Vedolizumab [DR:D08083] Upadacitinib hydrate [DR:D11048] Infliximab [DR:D02598] Adalimumab [DR:D02597] Golimumab [DR:D04358] Ustekinumab [DR:D09214] |
| Comment | - |
| Other DBs | ICD-11: DD71 ICD-10: K51 MeSH: D003093 OMIM: 612261 619398 |
| Reference | PMID:26339135 AUTHORS de Mattos BR, Garcia MP, Nogueira JB, Paiatto LN, Albuquerque CG, Souza CL, Fernandes LG, Tamashiro WM, Simioni PU TITLE Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments. JOURNAL Mediators Inflamm 2015:493012 (2015) DOI:10.1155/2015/493012 PMID:19923578 AUTHORS Abraham C, Cho JH TITLE Inflammatory bowel disease. JOURNAL N Engl J Med 361:2066-78 (2009) DOI:10.1056/NEJMra0804647 PMID:17068223 (IL23R) AUTHORS Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang H, Targan S, Datta LW, Kistner EO, Schumm LP, Lee AT, Gregersen PK, Barmada MM, Rotter JI, Nicolae DL, Cho JH TITLE A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. JOURNAL Science 314:1461-3 (2006) DOI:10.1126/science.1135245 PMID:18836448 (IL10) AUTHORS Franke A, Balschun T, Karlsen TH, Sventoraityte J, Nikolaus S, Mayr G, Domingues FS, Albrecht M, Nothnagel M, Ellinghaus D, Sina C, Onnie CM, Weersma RK, Stokkers PC, Wijmenga C, Gazouli M, Strachan D, McArdle WL, Vermeire S, Rutgeerts P, Rosenstiel P, Krawczak M, Vatn MH, Mathew CG, Schreiber S TITLE Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. JOURNAL Nat Genet 40:1319-23 (2008) DOI:10.1038/ng.221 PMID:33674380 (IL37) AUTHORS Zhang ZZ, Zhang Y, He T, Sweeney CL, Baris S, Karakoc-Aydiner E, Yao Y, Ertem D, Matthews HF, Gonzaga-Jauregui C, Malech HL, Su HC, Ozen A, Smith KGC, Lenardo MJ TITLE Homozygous IL37 mutation associated with infantile inflammatory bowel disease. JOURNAL Proc Natl Acad Sci U S A 118:e2009217118 (2021) DOI:10.1073/pnas.2009217118 PMID:22237417 (MST1) AUTHORS Hauser F, Deyle C, Berard D, Neukirch C, Glowacki C, Bickmann JK, Wenzel JJ, Lackner KJ, Rossmann H TITLE Macrophage-stimulating protein polymorphism rs3197999 is associated with a gain of function: implications for inflammatory bowel disease. JOURNAL Genes Immun 13:321-7 (2012) DOI:10.1038/gene.2011.88 |